MyDx Inc. (fka MYDX)

[Rascal1]

MYDX-Superior.Court.of.California.Demurrer.Rulings & Recent PR's

http://www.sandiego.courts.ca.gov/v3tr/ViewRulings.aspx?CaseNo=37-2017-00026331-CU-BT-CTL&SelDates=02/02/2018&EventId=1902311

SUPERIOR COURT OF CALIFORNIA,
DEPT.: EVENT DATE: EVENT TIME:
HALL OF JUSTICE TENTATIVE RULINGS - February 01, 2018
02/02/2018 10:30:00 AM C-66
COUNTY OF SAN DIEGO
February
01, 2018
JUDICIAL OFFICER:Kenneth J Medel
CASE NO.:
CASE CATEGORY:
EVENT TYPE:
CASE TITLE:
CASE TYPE:Civil - Unlimited Business Tort
Demurrer / Motion to Strike
37-2017-00026331-CU-BT-CTL
CDX INC VS DEWALD [IMAGED]
CAUSAL DOCUMENT/DATE FILED: Demurrer, 12/21/2017
stolo
Defendant's Demurrer to the Fifth Cause of Action for Negligent Interference is OVERRULED. The FAC alleges that there was a number of economic relationships that existed between the Plaintiffs and third parties. FAC ¶¶ 34; 76-79. The FAC further alleges that Dewald was aware of these relationships and yet still failed to act with due care with regard to the relationship between the Plaintiffs and the third parties and was aware that a lack of due care would lead to economic harm to the Plaintiffs. FAC ¶ 83. A duty of care need not arise solely out of privity of contract or some higher standard of fiduciary duty, but defendants have a general duty to act like a reasonable person with regard to foreseeable risk to others. See Dillon v. Legg, 68 Cal.2d 728, 741 (1968). The FAC need not allege that Dewald was the fiduciary of the Plaintiffs.
Defendant's Demurrer to the Seventh Cause of Action based on Bus. &.Prof Code, § 17200 is OVERRULED. "Engagement in business" is interpreted very broadly and the FAC's allegation that the moving party is an "investor and stock trader" satisfies the element of § 17200 requiring that the defendant be engaged in a business practice.
As to "restitution", California Code of Civil Procedure ("CCP") 430.10(e) does not allow for a defendant to demurrer a remedy.
Defendant's Demurrer to the Eighth Cause of Action for Civil Extortion is OVERRULED. The litigation privilege would not necessarily cover extortion. The Court has held that a lawyer's demand letter can constitute extortion as a matter of law, when a threat to report the recipient to the authorities regarding an alleged crime is accompanied by a demand for payment. Flatley v. Mauro, 39 Cal. App. 4th 299, 328 (2006).

------------------------------------------------------------------------

MYDX CANCELS REVERSE STOCK SPLIT AND OTHER RECENT PR'S
http://www.prnewswire.co.uk/news-releases/mydx-cancels-reverse-stock-split-665429493.html

MyDx Cancels Reverse Stock Split
Allows the Free Market to Take Its Course to Determine the Company Valuation

SAN DIEGO, Dec. 20, 2017 /PRNewswire/ -- MyDx, Inc. (OTC: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that based upon recent and anticipated developments for the Company, the board has decided to cancel its plans for the reverse stock split approved earlier this year.
"With the influx of interest for our MyDx360 services, including ancillary products such as the EcoSmartPenTM, as well as the progress we have made in the analysis of our 55K+ data points and the development of MyDx crowdsourced formulations, we are very optimistic about where the Company is headed into 2018. This, combined with the fact that recreational Cannabis will be legal in California in less than two weeks, gives us confidence that our valuation is better achieved without having to complete a reverse stock split at this time and simply allowing the free market to determine our value," said Daniel Yazbeck, CEO of MyDx.
The initial reason for ratifying and approving the reverse split was that the board believed that the Company's outstanding shares may have needed to be reduced with the primary goal of better enabling the Company to raise funds to finance growth as well as facilitating higher levels of institutional stock ownership where investment policies generally prohibit investments in lower-priced securities.
That said, the executive team has complete confidence in its current business strategy to attract a broader range of new shareholders at this price level. While the Company remains optimistic, there can be no assurance that this will be the case.
To learn more about MyDx, please visit www.mydxlife.com
To learn more about MyDx360™, please visit www.mydxlife.com/mydx360.
To learn more about the EcoSmartPen™, please visit www.mydxlife.com/ecosmartpen.
About MyDx, Inc.
MyDx, Inc. (OTC:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company's first product, MyDx®, also known as "My Diagnostic", is a patented multiuse hand-held chemical analyzer designed to help consumers and professional test for pesticides in food, chemicals in water, toxins in the air, and the safety and potency of cannabis samples, which is the initial focus of through the CannaDxTM application. CannaDx users have submitted over 40,000 crowdsourced datapoints revealing the chemical profile of the cannabis they are consuming and how its making them feel which feeds a data analytics platform, a SaaS business, as well as the biopharmaceutical division of MyDx. The company is committed to addressing areas of critical national need to promote public safety, transparency and regulation in the various markets we serve and hence its more immediate mission is to continue to develop smart devices as part of an ecosystem that crowdsources consumer generated preclinical data to drive innovation in the cannabis industry. For more information, please visit www.mydxlife.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.mydxlife.com/all-sec-filings or www.sec.gov.

Investor Contact:
MyDx Shareholder Communications
800.814.4550 ext. 4
[e-mail]

SOURCE MyDx, Inc.
Related Links
http://www.mydxlife.com

------------------------------------------------------------------------

https://ir.mydxlife.com/press-releases/detail/68/mydx-seeks-medical-device-designation-for-cannadx-and-the

Press Releases
Home / Investors / Press Releases

MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen
Download as PDF
December 14, 2017
Making MyDx Smart Devices More Affordable & Accessible for Canadian Cannabis Users
SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- MyDx, Inc. (OTC: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it submitted an application and is seeking medical device designation in Canada for its CannaDxTM Handheld Tester and its ECOSmartPenTM in order to make its products more accessible to medicinal users seeking to track and manage their consumption habits and prevent abuse.

According to the Institute of Health Economics, under the Food and Drugs Act, medical devices have a broad definition that includes any item sold to diagnose, treat, mitigate, or prevent a disease, disorder or abnormal physical state, or any of their symptoms.
MyDx products will be used to track crowdsourced herbal medicine by our customers to treat various ailments as well as monitor and track consumption habits (a feature shared by both the ECOSmartPen and the CannaDx Handheld Tester) to promote public safety and accountability. It's easy to see how MyDx products can fit within the confines of that description and the company is confident in its ability to gain approval. Still, there can be no assurance that it will gain or be granted such certifications.
Increases Affordability & Accessibility to MyDx Products Country-wide
Recently, Loblaws, a large Canadian supermarket chain, extended coverage for medical marijuana to its ~45,000 employees under policies managed by Manulife and Great-West Life. With a medical device classification, medicinal users would be able to seek reimbursement from their insurance providers for their MyDx devices, significantly lowering the overall cost to patients.
With the advent of new Health Canada Regulations in 2015, following the Supreme Court's ruling that users of medical marijuana should be permitted to consume the product in more varied forms than smoking dried buds, the demand for insurers to cover medical marijuana under benefit plans has increased exponentially according to a report done by Miller Thompson LLP. As a result, the country is beginning to see a shift in its healthcare landscape, which is becoming more marijuana friendly.
"Our goal is enable a more personalized medical experience for every patient by ensuring everyone has access to our smart devices and crowdsourced formulations," said Daniel Yazbeck, CEO of MyDx. "Our products are used all over the world today to help people Trust & Verify® their cannabis and to monitor and track their consumption habits."
Entry level MyDx Handheld Testers currently retail for $699 (plus tax & shipping). The EcoSmartPen is projected to be shipped in the first quarter of next year and the company is currently taking pre-orders on its website at www.mydxlife.com/ecosmartpen.
To learn more about the industry and MyDx, please visit www.meetmydx.com.
About MyDx, Inc.
MyDx, Inc. (OTC:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company's first product, MyDx®, also known as "My Diagnostic", is a patented multiuse hand-held chemical analyzer designed to help consumers and professional test for pesticides in food, chemicals in water, toxins in the air, and the safety and potency of cannabis samples, which is the initial focus of through the CannaDxTM application. CannaDx users have submitted over 40,000 crowdsourced datapoints revealing the chemical profile of the cannabis they are consuming and how its making them feel which feeds a data analytics platform, a SaaS business, as well as the biopharmaceutical division of MyDx. The company is committed to addressing areas of critical national need to promote public safety, transparency and regulation in the various markets we serve and hence its more immediate mission is to continue to develop smart devices as part of an ecosystem that crowdsources consumer generated preclinical data to drive innovation in the cannabis industry. For more information, please visit www.mydxlife.com.




ANOTHER POST:-----------------------------------------------------------

This is.the.beginning of.something.huge. I.was.hoping in my lifetime something like this would happen with MYDX and it could happen in 5 years or less!

Ok, months back(references to follow) I suggested how human Genomics are important because it is what MYDX has been saying all along, that each individual physiology is unique and so is how each physiology reacts to same cannabis strain. Phylos fits in perfect with the concept of cross referencing CannaDX sample test data with Phylos cannabis Genomics and now a feeling can be associated with a degree of accuracy to a specific cannabis genome, so now, the individual, not even knowing his/own gene sequence can identify with a specific cannabis plant for a specific ailment relief.

This cross-referencing of data makes each entity(Phylos and MYDX) codependent for generating even more meaningful data to offer the market place. This is the next step in the ultimate cost-effective human/cannabis genome project for medicinal purposes.

I’m not sure what he next step after this would be but eventually, hopefully in my lifetime as well MYDX will be involved in cross-referencing individual Genomics with cannabis Genomics where the individual would know with absolute certainty based on historical data what cannabis product to purchase to remedy a specific ailment or to provide a wanted reaction.

“Phylos uses genome sequencing technology to generate DNA “barcodes” that uniquely identify cannabis varieties. This information is important for basic scientific research, and it also serves as proof of existence that can be used to defend against attempts at patenting.”
http://www.phylosbioscience.com/about/data-policy/
Perhaps this can be used to fight of GW attempts at CBD patenting.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133208585
“Last year, the China Food and Drug Administration approved the sequencer as a medical device, allowing its use in clinical genetic testing...”

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132234994
http://www.prnewswire.com/news-releases/pharma-and-biotech-companies-significantly-investing-in-rd-focus-on-rising-demand-for-advanced-medicines-628164013.html Wow, according to this, est. 50Billion dollars is used by these companies alone are using on R&D investments specifically in "advanced medicine" alone:

"In just over a year ago, it's been estimated $50 billion was invested on pharmaceutical Research and Development activities majorly on oncology, diabetes, and autoimmune therapy classes, which is expected to propel the biotechnology services outsourcing market growth. Biotechnology and Pharmaceutical Companies with developments and recent market activity this week include: Moleculin Biotech, Inc., (NASDAQ: MBRX), XBiotech Inc. (NASDAQ: XBIT), GTx, Inc. (NASDAQ: GTXI), Agenus Inc. (NASDAQ: AGEN) and TrovaGene Inc. (NASDAQ: TROV)"

How many of these companies are applying research to the use of medicinal cannabis in the rising medicinal cannabis market? They are clearly focusing their attention on non-cannabis markets and will go through MYDX when the time is right for them which is most likely when medicinal cannabis is legal at the federal level. The more years, the more they will have to pay for all of MYDX's R&D investments in advanced medicinal cannabis vape pen. What effect will this have on current MYDX investors?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132627843
MYDX is the solution to an EXPOSED PROBLEM: unsafe black market weed. Before it was just black market weed, this by itself is not effective for MYDX but now that it's UNREGULATED HARMFUL BLACK MARKET WEED, the only chance consumers have of not being harmed by illegal unregulated weed is the MYDX CannaDX chemical analyzer with proven successful results! Once MYDX becomes PREMIER HOUSEHOLD CANNABIS QUALITY CONTROL backed by consumers and consumer confidence, what other companies will be around to compete? What direct competition does MYDX have?

MYDX major reasons why MYDX data is so valuable (followed by reference link):

"However, as MyDx began to analyze the data it accumulated from its testing devices, a much darker picture appeared - you cannot trust what dispensaries sell you."

"Today, if you were to go into any dispensary and ask for "Blue Dream", what do you think you would get? Would you get "Blue Dream"?
According to MyDx data, the answer is unequivocally NO!
Unfortunately, not all Blue Dreams are created equal, unveiling the biggest lie in cannabis. Whereas consumer products outside of cannabis enjoy a higher level of consistency and reliability brought on by stricter enforcement of consumer laws, the same cannot be said about the cannabis industry."

"Fortunately for MyDx users, brand names take a back seat to chemical profiles as MyDx tracks data based on sensory responses, interpreted chemical profiles, and an associated feeling or relief. So while you can't trust the brand name you purchase, you can Trust and Verify® chemical profiles and track how those profiles make you feel using MyDx, which has created another opportunity: green Active Pharmaceuticals Ingredients (gAPI)
"I believe extraction and formulation into a concentrate that can be delivered consistently to help patients find relief for their ailments and symptoms is the next logical step to achieving some level of consistency in the industry," stated Daniel Yazbeck, Chief Executive Officer of MyDx."

http://ir.cdxlife.com/press-releases/detail/59/a-problematic-truth-and-a-solution-in-the-making

MYDX Why gAPI is so valuable (link reference to follow):

"...we are now identifying the specific green Active Pharmaceutical Ingredients (gAPI) that can be derived from cannabis, as well as the dosage of each ingredient that should go into a formulation so it can be tailored for a specific therapy. This information not only supports an active engaged community, but also provides the basis for our Company to partner, sell and supply smart devices and formulations to the various communities we service so they can benefit from tailored cannabis therapies that meet their specific needs."

http://ir.cdxlife.com/press-releases/detail/59/a-problematic-truth-and-a-solution-in-the-making

MYDX is HIPPA compliant, important? You be the judge after considering the following (reference links to follow):

"We are finally getting to the heart of what ailments people are tracking and more importantly, what unique chemicals profiles are helping them find relief," stated Yazbeck. "By mining this HIPPA Compliant Data, we are now identifying the specific green Active Pharmaceutical Ingredients (gAPI) that can be derived from cannabis, as well as the dosage of each ingredient that should go into a formulation so it can be tailored for a specific therapy."

http://ir.cdxlife.com/press-releases/detail/59/a-problematic-truth-and-a-solution-in-the-making

Is HIPPA compliance important (reference link to follow)?

"When dealing with patient ePHI, having a HIPAA compliant provider offers practitioners multiple benefits and peace of mind against impending audits."

http://blog.corespace.com/the-benefits-of-a-hipaa-compliant-provider

Is this product helping consumers determine whether or not they want to smoke a certain strain of cannabis before they smoke it? Is this product helping consumers communicate with MYDX verification that a certain strain could have a certain effect for someone interested in similar results as research before they invest in a cannabis purchase? The answer to these quintessential questions is undoubtedly YES and this is what I love about MYDX and what it is doing for consumers through CannaDX. Big deal if someone tells me a certain strain works for them, I want to be able to test it for myself. MYDX will allow me to test a strain I've had that made me feel sick and caused vomiting and dizziness. I love that I will be able to test what strain that was so I know through the "trust and verify" process that I will never put that strain in my body ever again! This is just cannabis, MYDX is so much more but what it accomplishes is exactly what it set out to do from day one and that is allow consumers the opportunity to "trust and verify" something before they expose it to their bodies, and as far as AeroDX, I believe, there will be sensors you can place in a room that will monitor the air so that before someone enters it, they will be able to know if the air is toxic. For sure, if a room's air is toxic after you enter it, AeroDX will let you know. If someone hates this product or company, it can't be for these reasons, so that's what I will never understand about people who say they hate this company and products. I'm not going to ask questions leading to the conclusion that people involved in companies such as big pharma just don't want MYDX to succeed because it is a threat to their market share in their industry.